CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible from this website after logging in with the email address you submitted during registration. Surveys will be available online starting the first day of the symposium. You must complete the process by February 16, 2026 in order to receive your certificate. Certificates will be available online until August 1, 2026 and are printable directly from the website.
The AAFP has reviewed 26th Annual San Diego Heart Failure Winter Symposium:
Detecting, Preventing and Treating Heart Failure and deemed it acceptable for up to 12.50 Live AAFP Prescribed credit(s). Term of Approval is from 01/23/2026 to 01/24/2026. Physicians should claim only the credit commensurate with the extent of
their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as
equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's
Recognition Award. When applying for the AMA PRA, Prescribed credit earned must
be reported as Prescribed, not as Category 1.
The 26th Annual San Diego Heart Failure Winter Symposium - New Strategies for Detection, Prevention and
Treatment of Heart Failure aims to provide a comprehensive overview of how to best manage patients with heart failure at all stages of disease. This accredited program emphasizes practical aspects of heart failure management beginning with prevention of clinically manifest disease in patients at risk and extending to end-stage heart failure. Over the course of two days, the focused sessions that include lectures, case discussions and moderated panels will provide expert insight and personal experience that cover the full range of management options that are available for managing patients throughout the spectrum of heart failure. The agenda of the Winter 2026 Symposium includes content that extends from recognition of patients with cardiovascular-renal-metabolic syndrome (CRMS) who are risk of developing heart failure to the management of patients with symptomatic heart failure including those with cardiogenic shock or end-stage disease. Advances in drug and device therapy will receive extensive coverage throughout the Symposium. Insights into the recognition and management of less common (but not less important) causes of disease including genetic mutations are important areas that will be reviewed.
Throughout the Symposium, best practices and emerging strategies for diagnosis and treatment are emphasized. By combining case vignettes, patient narratives, didactic lectures and insightful panel discussions, attendees will have the opportunity to gain state of the art insights into the management of patients with heart failure. Our goal, as always, is to provide cutting edge information in a format that will enhance adaption of the knowledge that is gained into clinical practice.
This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.
At the conclusion of this activity, participants should be able to:
Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year. Heart failure is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. (Martin SS, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-e913). Data shows us that while heart failure is common, it is oftentimes unrecognized and misdiagnosed. Recent data also indicate that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (Joglar JA, et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156) are underutilized (Greene SJ, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):351-366). There is also significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF that has led to a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S., patients with HF received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010). As a consequence, despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.
This activity is in compliance with California Assembly Bills 1195 and 241 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity.
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.